Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human VEGF R1 /Flt-1 Protein, His Tag, 100µg  

Recombinant human VEGF R1 /Flt-1 Protein, His Tag, 100µg

Recombinant Human VEGF R1 /Flt-1 Protein Ser 27 - Asn 756, produced in human 293 cells (HEK293), His Tag

Synonym: recombinant human protein, FLT, VEGFR1, FLT1

More details

VE1-H5220-100

Availability: within 7 days

348,00 €

Background
Vascular endothelial growth factor receptor 1 (VEGFR1) also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.

Source
Recombinant Human VEGF R1 /Flt-1 Protein (rhVEGFR1) Ser 27 - Asn 756 (Accession # NP_002010.1) was produced in human 293 cells (HEK293).

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 83.0 kDa. The protein migrates as 110-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhVEGFR1 by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165, Tag Free (Cat. No. VE5-H4210) at 0.01 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Cat. No. VE1-H5220) with a linear range of 4-31 ng/mL (QC tested). Measured by its ability to bind ActiveMax ® Human VEGF165 (Cat. No. VE5-H4210) in the SPR assay (Biacore 2000) with an estimated KD of 0.1nM (Routinely tested).

References

(1) Shibuya M., et al., 1990, Oncogene 5:519-524.
(2) Kendall R.L., et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709.
(3) Seetharam L., et al., 1995, Oncogene 10:135-147.
(4) Barleon B., et al., 1996, Blood 87:3336-3343.
(5) Grunewald F.S., et al., 2010, Biochim. Biophys. Acta 1804:567-580.
(6) Iyer S., et al., 2010, J. Biol. Chem. 285:23779-23789.